» Articles » PMID: 38067222

Unexpected Differences in the Speed of Non-Malignant Versus Malignant Cell Migration Reveal Differential Basal Intracellular ATP Levels

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Dec 9
PMID 38067222
Authors
Affiliations
Soon will be listed here.
Abstract

Cellular locomotion is required for survival, fertility, proper embryonic development, regeneration, and wound healing. Cell migration is a major component of metastasis, which accounts for two-thirds of all solid tumor deaths. While many studies have demonstrated increased energy requirements, metabolic rates, and migration of cancer cells compared with normal cells, few have systematically compared normal and cancer cell migration as well as energy requirements side by side. Thus, we investigated how non-malignant and malignant cells migrate, utilizing several cell lines from the breast and lung. Initial screening was performed in an unbiased high-throughput manner for the ability to migrate/invade on collagen and/or Matrigel. We unexpectedly observed that all the non-malignant lung cells moved significantly faster than cells derived from lung tumors regardless of the growth media used. Given the paradigm-shifting nature of our discovery, we pursued the mechanisms that could be responsible. Neither mass, cell doubling, nor volume accounted for the individual speed and track length of the normal cells. Non-malignant cells had higher levels of intracellular ATP at premigratory-wound induction stages. Meanwhile, cancer cells also increased intracellular ATP at premigratory-wound induction, but not to the levels of the normal cells, indicating the possibility for further therapeutic investigation.

Citing Articles

Navigating the Collective: Nanoparticle-Assisted Identification of Leader Cancer Cells During Migration.

Alexandrova A, Kontareva E, Pustovalova M, Leonov S, Merkher Y Life (Basel). 2025; 15(1).

PMID: 39860067 PMC: 11766853. DOI: 10.3390/life15010127.

References
1.
Welch D, Hurst D . Defining the Hallmarks of Metastasis. Cancer Res. 2019; 79(12):3011-3027. PMC: 6571042. DOI: 10.1158/0008-5472.CAN-19-0458. View

2.
Steeg P . Targeting metastasis. Nat Rev Cancer. 2016; 16(4):201-18. PMC: 7055530. DOI: 10.1038/nrc.2016.25. View

3.
Sanchez-Laorden B, Viros A, Girotti M, Pedersen M, Saturno G, Zambon A . BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal. 2014; 7(318):ra30. DOI: 10.1126/scisignal.2004815. View

4.
Friedl P, Locker J, Sahai E, Segall J . Classifying collective cancer cell invasion. Nat Cell Biol. 2012; 14(8):777-83. DOI: 10.1038/ncb2548. View

5.
Friedl P . Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol. 2004; 16(1):14-23. DOI: 10.1016/j.ceb.2003.11.001. View